This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded SAFE, CNOB, LMT and more.
Stocks · News reference
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BofA Securities Upgrades Pharvaris to Buy From Neutral
BofA Securities has upgraded its rating for Pharvaris N.V. from Neutral to Buy, according to a report published on October 23, 2026.
Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR showed a
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review.